Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  398 results for ""Cytochrome P-450 CYP3A""

Your Filters

Publisher : springer
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions.

  • Authors : Li T; Phase I Clinical Trial Unit, The First Affiliated Hospital With Nanjing Medical University, Nanjing, 210029, China.; Department of Clinical Pharmacology, School of Pharmacy College, Nanjing Medical University, Nanjing, 211166, China.

Subjects: Drug Interactions* ; Epirubicin*/Epirubicin*/Epirubicin*/pharmacokinetics ; Epirubicin*/Epirubicin*/Epirubicin*/administration & dosage

  • Source: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Aug; Vol. 51 (4), pp. 367-384. Date of Electronic Publication: 2024 Mar 30.Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Cytochrome P450 activity in rheumatoid arthritis patients during continuous IL-6 receptor antagonist therapy.

  • Authors : Dunvald AD; Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, JB Winsløwsvej 19, 2, DK-5000, Odense C, Denmark.; Søltoft K

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/Arthritis, Rheumatoid*/drug therapy; Humans

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Dec; Vol. 79 (12), pp. 1687-1698. Date of Electronic Publication: 2023 Oct 13.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates.

  • Authors : Otsuka Y; Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., 2-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, 103-8411, Japan. .; Poondru S

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Rivaroxaban*; Male

  • Source: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2023 Oct; Vol. 50 (5), pp. 365-376. Date of Electronic Publication: 2023 Jun 21.Publisher: Springer Country of Publication: United States NLM ID: 101096520 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

A cocktail probe approach to evaluate the effect of hormones on the expression and activity of CYP enzymes in human hepatocytes with conditions simulating late stage of pregnancy.

  • Authors : Alshabi A; Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15261, USA.; Clinical Pharmacy Department, College of Pharmacy, Najran University, Najran, Saudi Arabia.

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Tandem Mass Spectrometry*; Humans

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Jun; Vol. 79 (6), pp. 815-827. Date of Electronic Publication: 2023 Apr 15.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Impacts of pregnane X receptor and cytochrome P450 oxidoreductase gene polymorphisms on trough concentrations of apixaban in patients with non-valvular atrial fibrillation.

  • Authors : Nakagawa J; Department of Pharmacy, Hirosaki University Hospital, 53 Hon-Cho, Hirosaki, Aomori, 036-8563, Japan.; Kinjo T

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Atrial Fibrillation*/Atrial Fibrillation*/Atrial Fibrillation*/drug therapy

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2023 Jan; Vol. 79 (1), pp. 127-135. Date of Electronic Publication: 2022 Nov 18.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Physiologically based pharmacokinetic combined BTK occupancy modeling for optimal dosing regimen prediction of acalabrutinib in patients alone, with different CYP3A4 variants, co-administered with CYP3A4 modulators and with hepatic impairment.

  • Authors : Xu L; Affiliated Hospital of Jiangxi University of Chinese Medicine, Jiangxi Province, Nanchang, 330006, China.; Yu S

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/Cytochrome P-450 CYP3A Inhibitors*/pharmacokinetics

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Sep; Vol. 78 (9), pp. 1435-1446. Date of Electronic Publication: 2022 Jun 09.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Editorial & Opinion

Response to: "Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time".

  • Authors : Kvitne KE; Section for Pharmacology, Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway. .; Hole K

Subjects: Cytochrome P-450 CYP3A* ; Hydroxycholesterols*; Biomarkers

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Nov; Vol. 78 (11), pp. 1865-1866. Date of Electronic Publication: 2022 Sep 13.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Utility of endogenous 4β-hydroxycholesterol as a biomarker to assess cytochrome P 450 3A (CYP3A) activity: not quite ready for prime time.

  • Authors : Tung NP; Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, 0657, USA.; Ma JD

Subjects: Cytochrome P-450 CYP3A* ; Hydroxycholesterols*; Biomarkers

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Nov; Vol. 78 (11), pp. 1863-1864. Date of Electronic Publication: 2022 Sep 13.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

Correlations between 4β-hydroxycholesterol and hepatic and intestinal CYP3A4: protein expression, microsomal ex vivo activity, and in vivo activity in patients with a wide body weight range.

  • Authors : Eide Kvitne K; Section for Pharmacology and Pharmaceutical Biosciences, Department of Pharmacy, University of Oslo, Blindern, P.O. Box 1068, 0316, Oslo, Norway. .; Hole K

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/metabolism ; Midazolam*

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Aug; Vol. 78 (8), pp. 1289-1299. Date of Electronic Publication: 2022 Jun 01.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
Academic Journal

The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients.

  • Authors : Wang XH; Department of Pharmacy, Rui-Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.; Shao K

Subjects: Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/Cytochrome P-450 CYP3A*/genetics ; Immunosuppressive Agents*/Immunosuppressive Agents*/Immunosuppressive Agents*/administration & dosage ; Immunosuppressive Agents*/Immunosuppressive Agents*/Immunosuppressive Agents*/pharmacokinetics

  • Source: European journal of clinical pharmacology [Eur J Clin Pharmacol] 2022 Aug; Vol. 78 (8), pp. 1261-1272. Date of Electronic Publication: 2022 May 10.Publisher: Springer Country of Publication: Germany NLM ID: 1256165 Publication Model: Print-Electronic Cited Medium:

Record details

Read More Add to Saved list
×
  • 1-10 of  398 results for ""Cytochrome P-450 CYP3A""